Abstract 1957: Drug Eluting Stents Have a High Rate of Restenosis in Cardiac Allograft Vasculopathy
INTRODUCTION Percutaneous coronary intervention (PCI) with either balloon angioplasty (PTCA) or bare metal stent (BMS) placement is associated with high rates of restenosis in patients with cardiac allograft vasculopathy (CAV), but the restenosis rate with drug eluting stents (DES) in this population is unknown.
HYPOTHESIS The hypothesis of this study is that there continues to be a high rate of restenosis after DES implantation when treating CAV.
METHODS We retrospectively analyzed all orthotopic heart transplant recipients between January 1986 and May 2006 who were treated with a PCI (including PTCA, BMS or DES) for CAV at a single heart transplant center. Angiographic data and restenosis rates (defined as greater than 50% stenosis) were collected from all patients who had subsequent coronary angiograms.
RESULTS PCI was performed on 74 coronary lesions in 35 patients an average of 7.7 ± 2.6 years after OHT. Follow-up angiograms > 6 months post-intervention were available for 85% of patients. A total of 61 interventions were performed including 17 cases of PTCA, 27 BMS and 17 DES. The binary restenosis rate was 65% for PTCA, 51% for bare metal stents and 23% for drug eluting stents.
CONCLUSION The results of this single center retrospective analysis suggest that cardiac transplant patients who receive drug eluting stents for the treatment of CAV experience high rates of restenosis, but less so than compared with PTCA or BMS implantation.